Phytoestrogens as inhibitors of the human progesterone metabolizing enzyme AKR1C1

Molecular and Cellular Endocrinology

Volumn 259, Issue 1-2, 2006, Pages 30-42

  Brožič, Petra ^a   Šmuc, Tina ^a   Gobec, Stanislav ^a   Rižner, Tea Lanišnik ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

20 Hydroxysteroid dehydrogenases; 3 ,5 Tetrahydroprogesterone; Aldo keto reductases; Neurosteroids; Progesterone

Indexed keywords

20ALPHA DIHYDROPROGESTERONE; 20ALPHA HYDROXYSTEROID DEHYDROGENASE; 3 ALPHA,5 ALPHA TETRAHYDROPROGESTERONE; 3 HYDROXYFLAVONE; 5 METOXYFLAVONE; 7 HYDROXYFLAVONE; ABIETIC ACID; APIGENIN; BIOCHANIN A; CHRYSIN; COUMARIN; COUMESTROL; DAIDZEIN; DIETHYLSTILBESTROL; EQUILIN; FLAVANONE; FLAVONE; FLAVONE DERIVATIVE; GENISTEIN; GLYCYRRHETINIC ACID; KAEMPFEROL; LUTEOLIN; NARINGENIN; PHYTOESTROGEN; PROGESTERONE; QUERCETIN; RESVERATROL; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZEARALENONE;

ANIMAL CELL; ARTICLE; ENZYME INHIBITION; ESCHERICHIA COLI; HORMONE ACTION; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

20-HYDROXYSTEROID DEHYDROGENASES; 3-HYDROXYSTEROID DEHYDROGENASES; BINDING SITES; COMPUTER SIMULATION; COUMARINS; ENZYME INHIBITORS; ESTRADIOL CONGENERS; ESTROGEN RECEPTOR MODULATORS; FLAVANONES; FLAVONES; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; ISOFLAVONES; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PHENANTHRENES; PHYTOESTROGENS; PROGESTERONE; PROGESTERONE REDUCTASE; PROTEIN BINDING; RECOMBINANT PROTEINS; STILBENES; ZEARALENONE;

EID: 33748848304     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2006.08.001     Document Type: Article

References (72)

1. Adamski J., and Jakob F.J. A quide to 17β-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol. 171 (2001) 1-4
2. Adlercreutz H., Markkanen H., and Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 342 (1993) 1209-1210
3. Adlercreutz H., and Mazur W. Phyto-estrogens and western disease. Ann. Med. 29 (1997) 95-120
4. Akhmedkhanov A., Zeleniuch-Jacquotte A., and Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer. Ann. NY Acad. Sci. 943 (2001) 296-315
5. Bauman D.R., Steckelbroeck S., and Penning T.M. The roles of aldo-keto reductases in steroid hormone action. Drug News Perspect. 17 (2004) 563-578
6. Bauman D.R., Rudnick S., Szewczuk L.M., Jin Y., Gopishetty S., and Penning T.M. Development of non-steroidal anti-inflammatory drug (NSAID) analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes. Mol. Pharmacol. 67 (2005) 60-68
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
8. Brinton R.D., Proffitt P., Tran J., and Luu R. Equilin, a principal component of the estrogen replacement therapy premarin, increases the growth of corctical neurons via an NMDA receptor-mediated mechanism. Exp. Neurol. 147 (1997) 211-220
9. Campagnoli C., Abba C., Ambroggio S., and Peris C. Pregnancy, progesterone and progestins in relation to breast cancer risk. J. Steroid Biochem. Mol. Biol. 97 (2005) 441-450
10. Campagnoli C., Clavel-Chapelon F., Kaaks R., Peris C., and Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J. Steroid Biochem. Mol. Biol. 96 (2005) 95-108
11. Carrusi D. Phytoestrogens as hormone replacement therapy: an evidence based approach. Prim. Care Update Ob./Gyns. 7 (2000) 253-259
12. Cos P., De Bruyne T., Apers S., Vanden Berghe D., Pieters L., and Vlietinck A.J. Phytoestrogens: recent developments. Planta Med. 69 7 (2003) 589-599
13. Couture J.F., Cantin L., Legrand P., Luu-The V., Labrie F., and Breton R. Expression, crystallization and preliminary X-ray analysis of human and rabbit 20α-hydroxysteroid dehydrogenase in complex with NADP(H) and various substrates. Acta Cryst. D 58 (2002) 135-139
14. Couture J.F., Legrand P., Cantin L., Luu-The V., Labrie F., and Breton R. Human 20α-hydroxysteroid dehydrogenase: crystallographic and site-directed mutagenesis studies lead to the identification of an alternative binding site for C21-steroids. J. Mol. Biol. 331 (2003) 593-604
15. Deluca D., Krazeisen A., Breitling R., Prehn C., Moller G., and Adamski J. Inhibition of 17beta-hydroxysteroid dehydrogenases by phytoestrogens: comparison with other steroid metabolizing enzymes. J. Steroid Biochem. Mol. Biol. 2-5 (2005) 285-292
16. Erlund I., Meririnne E., Alfthan G., and Aro A. Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in human after ingestion of orange juice and grapefruit juice. J. Nutr. 131 (2001) 235-241
17. Gasteiger J., and Marsili M. Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron 36 (1980) 3219-3228
18. Gizard F., Robillard R., Gervois P., Faucompre A., Revillion F., Peyrat J.-F., Hum W.D., and Staels B. Progesterone inhibits human breast cancer cell growth through transcriptional upregulation of the cyclin-dependent kinase inhibitor p27 gene. FEBS Lett. 579 (2005) 5535-5541
19. Griffin L.D., and Mellon S.H. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Natl. Acad. Sci. USA 96 (1999) 13512-13517
20. Higaki Y., Usami N., Shintani S., Ishikura S., El-Kabbani O., and Hara A. Selective and potent inhibitors of human 20α-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chem. Biol. Interact. 143/144 (2003) 503-513
21. Hyndman D., Bauman D.R., Heredia V.V., and Penning T.M. The aldo-keto reductase superfamily homepage. Chem. Biol. Interact. 1 (2003) 621-631
22. Jacobs M.N., and Lewis D.F. Steroid hormone receptors and dietary ligands: a selective review. Proc. Nutr. Soc. 61 (2002) 105-122
23. Jefferson W.N., and Newbold R.R. Potential endocrine-modulating effect of various phytoestrogens in the diet. Nutrition 16 (2000) 658-662
24. Jez J.M., Schlegel B.P., and Penning T.M. Characterization of the substrate binding site in rat liver 3α-hydroxysteroid/dihydrodiol dehydrogenase. J. Biol. Chem. 271 (1996) 30190-30198
25. Jez J.M., Flynn T.G., and Penning T.M. A new nomenclature for the aldo-keto reductase superfamily. Biochem. Pharmacol. 54 (1997) 639-647
26. Ji Q., Aoyama C., Nien Y.-D., Liu P.I., Chen P.K., Chang L., Stanczyk F.Z., and Stolz A. Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling. Cancer Res. 64 (2004) 7610-7617
27. Jin Y., and Penning T.M. Molecular docking simulations of steroid substrates into human cytosolic hydroxysteroid dehydrogenases (AKR1C1 and AKR1C2): insight into positional and stereochemical preferences. Steroids 71 (2006) 380-391
28. Kirk C.J., Harris R.M., Wood D.M., Waring R.H., and Hughes P.J. Do dietary phytoestrogens influence susceptibility to hormone-dependent cancer by disrupting the metabolism of endogenous estrogens?. Biochem. Soc. Trans. 29 (2001) 209-215
29. Komoto J., Yamada T., Watanabe K., and Takusaqawa F. Crystal structure of human prostaglandin F synthase (AKR1C3). Biochemistry 43 (2004) 2188-2198
30. Krazeisen A., Breitling R., Moeller G., and Adamski J. Phytoestrogens inhibit human 17β-hydroxysteroid dehydrogenase type 5. Mol. Cell. Endocrinol. 171 (2001) 151-162
31. Krazeisen A., Breitling R., Moeller G., and Adamski J. Human 17β-hydroxysteroid dehydrogenase type 5 is inhibited by dieatary flavonoids. Adv. Exp. Med. Biol. 505 (2002) 151-161
32. Kristan K., Krajnc K., Konc J., Gobec S., Stojan J., and Lanišnik Rižner T. Phytoestrogens as inhibitors of fungal 17β-hydroxysteroid dehydrogenase. Steroids 70 (2005) 626-635
33. Lanišnik Rižner T., Lin H.K., Peehl D.M., Steckelbroeck S., Bauman D.R., and Penning T.M. Role of human type 3 3α-hydroxysteroid dehydrogenase (AKR1C2) in androgen metabolism of prostate cells. Endocrinology 144 (2003) 2922-2932
34. Lanišnik Rižner T., Šmuc T., Rupreht R., Šinkovec J., and Penning T.M. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol. Cell. Endocrinol. 248 (2006) 126-135
35. Le Bail J.-C., Champavier Y., Chulia A.-J., and Habrioux G. Effects of phytoestrogens on aromatase, 3β and 17β-hydroxysteroid dehydrogenase activities and human breast cancer. Life Sci. 66 (2000) 1281-1291
36. Le Bail J.-C., Pouget C., Fagnere C., Basly J.-P., Chulia A.-J., and Habrioux G. Chalcones are potent inhibitors of aromatase and 17β-hydroxysteroid dehydrogenase activities. Life Sci. 68 (2001) 751-761
37. Le Lain R., Nicholls P.J., Smith H.J., and Mahrlouie F.H. Inhibitors of human and rat testes microsomal 17β-hydroxysteroid dehydrogenase (17β-HSD) as potent agents for prostatic cancer. J. Enzyme Inhib. 16 (2001) 35-45
38. Le Lain R., Barrell K.J., Saeed G.S., Nicholls P.J., Simons C., Kirby A., and Smith H.J. Some coumarins and triphenylethene derivatives as inhibitors of human testes microsomal 17β-hydroxysteroid dehydrogenase (17β-HSD type 3): further studies with tamoxifen on the rat testes microsomal enzyme. J. Enzyme Inhib. 17 (2002) 93-100
39. Lephart E.D., Thompson J.M., Setchell K.D.R., Adlercreutz H., and Weber K.S. Phytoestrogens decrease brain calbinidin-binding proteins but do not alter hypothalamic androgen metabolizing enzymes in adult male rats. Brain Res. 859 (2000) 123-131
40. Lephart E.D., Lund T.D., and Horvath T.L. Brain androgen and progesterone metabolizing enzymes: biosynthesis, distribution and function. Brain Res. Rev. 37 (2001) 25-37
41. Lewis M.J., Wiebe J.P., and Heathcote J.G. Expresssion of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 4 (2004) 27
42. Mage P.J., and Rowland I.R. Phyto-estrogens, their mechanism of action: current evidence for a role in breast and prostate caner. Br. J. Nutr. 91 (2004) 513-531
43. Makela S., Poutanen M., Lehtimaki J., Kostian M.-L., Santii R., and Vihko R. Estrogen-specific 17β-hydroxysteroid oxidoreductase type 1 (E.C. 1.1.1.62) as a possible target for the action of phytoestrogens. Proc. Soc. Exp. Biol. Med. 208 (1995) 51-59
44. Makela S., Poutanen M., Kostian M.L., Lehtimaki N., Strauss L., Santii R., and Vihko R. Inhibiton of 17β-hydroxysteroid oxidoreductase by flavonoids in breast and prostate cancer cells. Proc. Soc. Exp. Biol. Med. 217 (1998) 306-310
45. Mehler E.L., and Solmajer T. Electrostatic effects in proteins-comparison of dielectric and charge models. Protein Eng. 4 (1991) 903-910
46. Mindnich R., Moeller G., and Adamski J. The role of 17beta-hydroxysteroid dehydrogenases. Mol. Cell. Endorinol. 218 (2004) 7-20
47. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comp. Chem. 19 (1998) 1662-1693
48. Nobel S., Abrahmsen L., and Oppermann U. Metabolic conversion as a pre-receptor control mechanism for lipophilic hormones. Eur. J. Biochem. 268 (2001) 4113-4125
49. Ohno S., Shinoda S., Toyoshima S., Nakazawa H., Makino T., and Nakajin S. Effects of flavonoid phytochemicals on cortisol production and on activities of steroidogenic enzymes in human adrenocortical H295R cells. J Steroid Biochem. Mol. Biol. 80 (2002) 355-363
50. Ohno S., Matsumoto N., Watanabe M., and Nakajin S. Flavonoid inhibition of overexpressed human 3β-hydroxysteroid dehydrogenase type II. J Steroid Biochem. Mol. Biol. 88 (2004) 175-182
51. Paganga G., and Rice-Evans C.A. The identification of flavonoids as glycosides in human plasma. FEBS Lett. 401 (1997) 78-82
52. Pawlak K.J., Zhang G., and Wiebe J.P. Membrane 5α-pregnane-3,20-dione (5αP) receptors in MCF-7 and MCF-10A breast cancer cells are up-regulated by estradiol and 5αP and down-regulated by the progesterone metabolites, 3α-dihydroprogesterone and 20α-dihydroprogesterone, with associated changes in cell proliferation and detachment. J. Steroid Biochem. Mol. Biol. 97 (2005) 278-288
53. Peltoketo H., Luu-The V., Simard J., and Adamski J. 17β-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. J. Mol. Endocrinol. 23 (1999) 1-11
54. Penning T.M. Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr. Rev. 18 (1997) 281-305
55. Penning T.M., Burczynski M.E., Jez M.E., Hung C.F., Lin H.K., Ma H., Moore M., Palackal N., and Ratnam K. Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex steroids. Biochem. J. 351 (2000) 67-77
56. Penning T.M. Hydroxysteroid dehydrogenases and pre-receptor regulation of steroid hormone action. Human Reprod. Update 9 (2003) 193-205
57. Poirier D. Inhibitors of 17β-hydroxysteroid dehydrogenases. Curr. Med. Chem. 10 (2003) 453-477
58. Rosselli M., Reinhart K., Imthurn B., Keller P.J., and Dubey R.K. Cellular and biochemical mechanisms by which environmental oestrogens influence reproductive function. Human Reprod. Update 6 (2000) 332-350
59. Santner S.J., and Santen R.J. Inhibition of estrone sulfatase and 17β-hydroxysteroid dehydrogenase by antiestrogens. J. Steroid Biochem. Molec. Biol. 45 (1993) 383-390
60. +. Proc. Natl. Acad. Sci. USA 96 (1999) 840-845
61. Schweitzer R.A.S., Atanasov A.G., Frey B.M., and Odermatt A. A rapid screening asay for inhibitors of 11β-hydroxysteroid dehydrogenases (11β-HSD): flavone selectively inhibits 11β-HSD1 reductase activity. Mol. Cell. Endocrinol. 212 (2003) 41-49
62. Sitruk-Ware R., and Plu-Bureau G. Exogenous progestagens and the human breast. Maturitas 29 (2004) 58-66
63. Steckelbroeck S., Jin Y., Gopishetty S., Oyesanmi B., and Penning T.M. Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. J. Biol. Chem. 279 (2004) 10784-10795
64. Tham D.M., Christopher D., Gardner D., and Haskell W.L. Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J. Clin. Endocrinol. Metab. 83 (1998) 2223-2235
65. Usami N., Yamamoto T., Shintani S., Higaki Y., Ishikura S., Katagiri Y., and Hara A. Substrate specificity of human 3(20)α-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol. Pharm. Bull. 25 (2002) 441-445
66. Weber K.S., Jacobson N.A., Setchell K.D., and Lephart E.D. Brain aromatase and 5alpha-reductase, regulatory behaviors and testosterone levels in adult rats on phytoestrogen diets. Proc. Soc. Exp. Biol. Med. 221 (1999) 131-135
67. Weiner S.J., Kollman P.A., Case D.A., Singh U.C., Ghio C., Alagona G., Profeta S., and Weiner P. A new force-field for molecular mechanical simulation of nucleic acids and proteins. J. Am. Chem. Soc. 106 (1984) 765-784
68. Wiebe J.P., Muzia D., Hu J., Szwajcer D., Hill S.A., and Seachrist J.L. The 4-pregnane and 5α-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Res. 60 (2000) 936-943
69. Wiebe J.P., and Lewis M.J. Activity and expression of progesterone metabolizing 5α-reductase, 20α-hydroxysteroid dehydrogenase and 3α(β) hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cell. BMC Cancer 3 (2003) 9
70. Wiebe J.P., Lewis M.J., Cialacu V., Pawlak K.J., and Zhang G. The role of progesterone metabolites in breast cancer: potential for new diagnostics and therapeutics. J. Steroid. Biochem. Mol. Biol. 93 (2005) 201-208
71. Wuttke W., Jarry H., Westphalen S., Christoffel V., and Seidlova-Wuttke D. Phytoestrogens for hormone replacement therapy?. J. Steroid Biochem. Mol. Biol. 83 (2002) 133-147
72. Yellayi S., Naaz A., Szewczykowski M.A., Sato T., Woods J.A., Chang J., Segre M., Allred C.D., Helferich W.G., and Cooke P.S. The phytoestrogen genistein induces thymic and immune changes: a human health concern?. Proc. Natl. Acad. Sci. USA 99 (2002) 7616-7621